PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31142766-0 2019 Generation of new hair cells by DNA methyltransferase (Dnmt) inhibitor 5-azacytidine in a chemically-deafened mouse model. Azacitidine 71-84 DNA methyltransferase (cytosine-5) 1 Mus musculus 32-53 31142766-0 2019 Generation of new hair cells by DNA methyltransferase (Dnmt) inhibitor 5-azacytidine in a chemically-deafened mouse model. Azacitidine 71-84 DNA methyltransferase (cytosine-5) 1 Mus musculus 55-59 31142766-2 2019 This study aims to evaluate the ability of DNA methyltransferase (Dnmt) inhibitor 5-azacytidine (5-aza) to generate outer hair cells (OHCs) in a chemically-deafened adult mouse model. Azacitidine 82-95 DNA methyltransferase (cytosine-5) 1 Mus musculus 43-64 31142766-2 2019 This study aims to evaluate the ability of DNA methyltransferase (Dnmt) inhibitor 5-azacytidine (5-aza) to generate outer hair cells (OHCs) in a chemically-deafened adult mouse model. Azacitidine 82-95 DNA methyltransferase (cytosine-5) 1 Mus musculus 66-70 31142766-2 2019 This study aims to evaluate the ability of DNA methyltransferase (Dnmt) inhibitor 5-azacytidine (5-aza) to generate outer hair cells (OHCs) in a chemically-deafened adult mouse model. Azacitidine 82-87 DNA methyltransferase (cytosine-5) 1 Mus musculus 43-64 31142766-2 2019 This study aims to evaluate the ability of DNA methyltransferase (Dnmt) inhibitor 5-azacytidine (5-aza) to generate outer hair cells (OHCs) in a chemically-deafened adult mouse model. Azacitidine 82-87 DNA methyltransferase (cytosine-5) 1 Mus musculus 66-70 31142766-9 2019 Quantitative PCR study indicates that 5-aza may function through Dnmt1 inhibition. Azacitidine 38-43 DNA methyltransferase (cytosine-5) 1 Mus musculus 65-70 31142766-10 2019 The results of this report suggest that the Dnmt inhibitor 5-aza may promote hair cell regeneration in a chemically-deafened mouse model. Azacitidine 59-64 DNA methyltransferase (cytosine-5) 1 Mus musculus 44-48 30586565-6 2019 A DNA methyltransferase (DNMT) inhibitor (5-aza-2"-deoxycytidine; 5-aza) was used for demethylation and the relative beta-catenin expression levels were measured to assess overactivity of the canonical Wnt signaling pathway. Azacitidine 42-47 DNA methyltransferase (cytosine-5) 1 Mus musculus 2-23 30586565-6 2019 A DNA methyltransferase (DNMT) inhibitor (5-aza-2"-deoxycytidine; 5-aza) was used for demethylation and the relative beta-catenin expression levels were measured to assess overactivity of the canonical Wnt signaling pathway. Azacitidine 42-47 DNA methyltransferase (cytosine-5) 1 Mus musculus 25-29 27536218-1 2016 The DNA methyltransferase (DNMT) inhibitor 5-azacytidine (5-aza) causes genomic demethylation to regulate gene expression. Azacitidine 43-56 DNA methyltransferase (cytosine-5) 1 Mus musculus 4-25 28318634-5 2017 The increased expression of Dnmt1 was attenuated after treatment with 5-azacytidine or 5-aza-2"-deoxycytidine or Dnmt1 knockdown, accompanied by restored decreased podocyte slit diaphragm proteins resulting from hypermethylation and improved podocyte motility. Azacitidine 70-83 DNA methyltransferase (cytosine-5) 1 Mus musculus 28-33 29634418-6 2018 DNA methyltransferase inhibitor, 5-AzaC, concomitantly upregulated the protein levels of GFRA4, as well as DNA methyltransferase1 (DNMT1) and DNMT2 in SH-5YSY cells. Azacitidine 33-39 DNA methyltransferase (cytosine-5) 1 Mus musculus 107-129 29634418-6 2018 DNA methyltransferase inhibitor, 5-AzaC, concomitantly upregulated the protein levels of GFRA4, as well as DNA methyltransferase1 (DNMT1) and DNMT2 in SH-5YSY cells. Azacitidine 33-39 DNA methyltransferase (cytosine-5) 1 Mus musculus 131-136 27713144-12 2016 Consistent with these findings, RGS6-/- mice treated with CP-31398, a p53-stablizing agent, and/or 5-Aza, a DNMT1 inhibitor, are protected from BBN-induced tumorigenesis. Azacitidine 99-104 DNA methyltransferase (cytosine-5) 1 Mus musculus 108-113 27536218-1 2016 The DNA methyltransferase (DNMT) inhibitor 5-azacytidine (5-aza) causes genomic demethylation to regulate gene expression. Azacitidine 43-56 DNA methyltransferase (cytosine-5) 1 Mus musculus 27-31 27536218-1 2016 The DNA methyltransferase (DNMT) inhibitor 5-azacytidine (5-aza) causes genomic demethylation to regulate gene expression. Azacitidine 43-48 DNA methyltransferase (cytosine-5) 1 Mus musculus 4-25 27536218-1 2016 The DNA methyltransferase (DNMT) inhibitor 5-azacytidine (5-aza) causes genomic demethylation to regulate gene expression. Azacitidine 43-48 DNA methyltransferase (cytosine-5) 1 Mus musculus 27-31 27197203-5 2016 A combination of the DNMT inhibitor 5-azacytidine and the HDAC inhibitor butyrate markedly reduced CSC abundance and increased the overall survival in this mouse model. Azacitidine 36-49 DNA methyltransferase (cytosine-5) 1 Mus musculus 21-25 27295295-6 2016 Pharmacological inhibition of DNA methyltransferase 1 (DNMT1) with 5-Aza-dC or knockdown of DNMT1 prevented the downregulation of macrophage ABCA1 expression, suggesting a role of DNA methylation in ABCA1 expression. Azacitidine 67-72 DNA methyltransferase (cytosine-5) 1 Mus musculus 30-53 27295295-6 2016 Pharmacological inhibition of DNA methyltransferase 1 (DNMT1) with 5-Aza-dC or knockdown of DNMT1 prevented the downregulation of macrophage ABCA1 expression, suggesting a role of DNA methylation in ABCA1 expression. Azacitidine 67-72 DNA methyltransferase (cytosine-5) 1 Mus musculus 55-60 23423140-4 2013 Specifically, we show that decreasing DNA methylation by inhibiting the activity of DNA methyltransferase (DNMT) with systemic administration of the FDA-approved drug, 5-azacitidine (5-AzaC) prevents excessive alcohol use in mice. Azacitidine 168-181 DNA methyltransferase (cytosine-5) 1 Mus musculus 84-105 26224577-7 2015 In contrast, inhibition of DNMT activity with 5-azacytidine treatment decreased global DNA methylation levels and blocked the increased expression of several HCM genes (Myh7, Gata4, Mef2c, Nfatc1, Myh7b, Tnni3, and Bnp) observed with DBcAMP treatment. Azacitidine 46-59 DNA methyltransferase (cytosine-5) 1 Mus musculus 27-31 23423140-4 2013 Specifically, we show that decreasing DNA methylation by inhibiting the activity of DNA methyltransferase (DNMT) with systemic administration of the FDA-approved drug, 5-azacitidine (5-AzaC) prevents excessive alcohol use in mice. Azacitidine 168-181 DNA methyltransferase (cytosine-5) 1 Mus musculus 107-111 23423140-4 2013 Specifically, we show that decreasing DNA methylation by inhibiting the activity of DNA methyltransferase (DNMT) with systemic administration of the FDA-approved drug, 5-azacitidine (5-AzaC) prevents excessive alcohol use in mice. Azacitidine 183-189 DNA methyltransferase (cytosine-5) 1 Mus musculus 84-105 23423140-4 2013 Specifically, we show that decreasing DNA methylation by inhibiting the activity of DNA methyltransferase (DNMT) with systemic administration of the FDA-approved drug, 5-azacitidine (5-AzaC) prevents excessive alcohol use in mice. Azacitidine 183-189 DNA methyltransferase (cytosine-5) 1 Mus musculus 107-111 34150002-13 2021 DNMT1 was increased while STAT3, PTEN and TSC2 were decreased by 5-AZA-DC. Azacitidine 65-70 DNA methyltransferase (cytosine-5) 1 Mus musculus 0-5 22349820-3 2012 To gain insight into the source of these mutations, we first tested the hypothesis that the mutagenic effect of 5-Aza-dC may be directly mediated through the DNA methyltransferase 1 (DNMT1) covalently trapped in 5-Aza-dC-substituted DNA. Azacitidine 112-117 DNA methyltransferase (cytosine-5) 1 Mus musculus 158-181 22349820-3 2012 To gain insight into the source of these mutations, we first tested the hypothesis that the mutagenic effect of 5-Aza-dC may be directly mediated through the DNA methyltransferase 1 (DNMT1) covalently trapped in 5-Aza-dC-substituted DNA. Azacitidine 112-117 DNA methyltransferase (cytosine-5) 1 Mus musculus 183-188 22349820-8 2012 Thus, our results indicate that the formation of DNMT1 adducts is the prevalent mechanism of 5-Aza-dC-induced genome rearrangements, although hypomethylation per se may still contribute. Azacitidine 93-98 DNA methyltransferase (cytosine-5) 1 Mus musculus 49-54 20348135-4 2010 We suggest that adducts formed between DNMT1 and 5-aza-dC molecules in DNA induce a ubiquitin-E3 ligase activity which preferentially targets free DNMT1 molecules for degradation by the proteasome. Azacitidine 49-54 DNA methyltransferase (cytosine-5) 1 Mus musculus 39-44 20348135-4 2010 We suggest that adducts formed between DNMT1 and 5-aza-dC molecules in DNA induce a ubiquitin-E3 ligase activity which preferentially targets free DNMT1 molecules for degradation by the proteasome. Azacitidine 49-54 DNA methyltransferase (cytosine-5) 1 Mus musculus 147-152 34906184-2 2021 The covalent DNMT1 inhibitors 5-azacytidine and decitabine are widely used in research to reduce DNA methylation levels, but they impart severe cytotoxicity which limits their demethylation capability and confounds interpretation of experiments. Azacitidine 30-43 DNA methyltransferase (cytosine-5) 1 Mus musculus 13-18 20062804-8 2010 Furthermore, treatment of TRAMP C1 cells with DNA methyltransferase (DNMT) inhibitor 5-aza-2"-deoxycytidine (5-aza) and histone deacetylase (HDAC) inhibitor trichostatin A (TSA) restored the expression of Nrf2 as well as the induction of NQO1 in TRAMP C1 cells. Azacitidine 85-90 DNA methyltransferase (cytosine-5) 1 Mus musculus 46-67 20062804-8 2010 Furthermore, treatment of TRAMP C1 cells with DNA methyltransferase (DNMT) inhibitor 5-aza-2"-deoxycytidine (5-aza) and histone deacetylase (HDAC) inhibitor trichostatin A (TSA) restored the expression of Nrf2 as well as the induction of NQO1 in TRAMP C1 cells. Azacitidine 85-90 DNA methyltransferase (cytosine-5) 1 Mus musculus 69-73 12417732-9 2002 Among the DNA methyltransferases, both Dnmt1 and Dnmt3a were associated with the MT-I promoter in the lymphosarcoma cells, and association of Dnmt1 decreased with time after treatment with 5-AzaC. Azacitidine 189-195 DNA methyltransferase (cytosine-5) 1 Mus musculus 39-44 12417732-9 2002 Among the DNA methyltransferases, both Dnmt1 and Dnmt3a were associated with the MT-I promoter in the lymphosarcoma cells, and association of Dnmt1 decreased with time after treatment with 5-AzaC. Azacitidine 189-195 DNA methyltransferase (cytosine-5) 1 Mus musculus 142-147 34801707-7 2022 Then, DNA methyltransferase (DNMT) inhibitor 5-Aza-2"-deoxycytidine (5-Aza) treatment enhanced EI24 expression and alleviated EMT in high glucose-treated HK2 cells and the kidneys of diabetic mice. Azacitidine 69-74 DNA methyltransferase (cytosine-5) 1 Mus musculus 6-27 34801707-7 2022 Then, DNA methyltransferase (DNMT) inhibitor 5-Aza-2"-deoxycytidine (5-Aza) treatment enhanced EI24 expression and alleviated EMT in high glucose-treated HK2 cells and the kidneys of diabetic mice. Azacitidine 69-74 DNA methyltransferase (cytosine-5) 1 Mus musculus 29-33 34503994-2 2021 Two DNMT1 depleting agents aza-dCyd (5-aza-2"-deoxycytidine, decitabine) and aza-Cyd (5-aza-cytidine, azacitidine) are currently used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, and have also been investigated for non-oncology indications such as sickle cell disease. Azacitidine 77-84 DNA methyltransferase (cytosine-5) 1 Mus musculus 4-9 34503994-2 2021 Two DNMT1 depleting agents aza-dCyd (5-aza-2"-deoxycytidine, decitabine) and aza-Cyd (5-aza-cytidine, azacitidine) are currently used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, and have also been investigated for non-oncology indications such as sickle cell disease. Azacitidine 86-100 DNA methyltransferase (cytosine-5) 1 Mus musculus 4-9 34503994-2 2021 Two DNMT1 depleting agents aza-dCyd (5-aza-2"-deoxycytidine, decitabine) and aza-Cyd (5-aza-cytidine, azacitidine) are currently used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, and have also been investigated for non-oncology indications such as sickle cell disease. Azacitidine 102-113 DNA methyltransferase (cytosine-5) 1 Mus musculus 4-9 32709850-5 2020 Importantly, we show that the flanking sequence preferences of DNMT1 highly correlate with genomic methylation in human and mouse cells, and 5-azacytidine triggered DNA demethylation is more pronounced at CpG sites with flanks disfavored by DNMT1. Azacitidine 141-154 DNA methyltransferase (cytosine-5) 1 Mus musculus 241-246 33316384-9 2021 Strikingly, either JNK2-specific inhibition or genetic JNK2 depletion or DNMT1 inhibition (by an inhibitor 5-Azacytidine) completely abolished BAW-evoked behavioral deficits. Azacitidine 107-120 DNA methyltransferase (cytosine-5) 1 Mus musculus 73-78 32580634-0 2020 High Throughput Screen Identifies the DNMT1 (DNA Methyltransferase-1) Inhibitor, 5-Azacytidine, as a Potent Inducer of PTEN (Phosphatase and Tensin Homolog): Central Role for PTEN in 5-Azacytidine Protection Against Pathological Vascular Remodeling. Azacitidine 81-94 DNA methyltransferase (cytosine-5) 1 Mus musculus 38-43 32580634-0 2020 High Throughput Screen Identifies the DNMT1 (DNA Methyltransferase-1) Inhibitor, 5-Azacytidine, as a Potent Inducer of PTEN (Phosphatase and Tensin Homolog): Central Role for PTEN in 5-Azacytidine Protection Against Pathological Vascular Remodeling. Azacitidine 81-94 DNA methyltransferase (cytosine-5) 1 Mus musculus 45-68 32580634-0 2020 High Throughput Screen Identifies the DNMT1 (DNA Methyltransferase-1) Inhibitor, 5-Azacytidine, as a Potent Inducer of PTEN (Phosphatase and Tensin Homolog): Central Role for PTEN in 5-Azacytidine Protection Against Pathological Vascular Remodeling. Azacitidine 183-196 DNA methyltransferase (cytosine-5) 1 Mus musculus 38-43 32580634-0 2020 High Throughput Screen Identifies the DNMT1 (DNA Methyltransferase-1) Inhibitor, 5-Azacytidine, as a Potent Inducer of PTEN (Phosphatase and Tensin Homolog): Central Role for PTEN in 5-Azacytidine Protection Against Pathological Vascular Remodeling. Azacitidine 183-196 DNA methyltransferase (cytosine-5) 1 Mus musculus 45-68 32580634-6 2020 Following in vitro confirmation, we focused on 5-azacytidine, a DNMT1 (DNA methyltransferase-1) inhibitor, for further analysis. Azacitidine 47-60 DNA methyltransferase (cytosine-5) 1 Mus musculus 64-69 32580634-6 2020 Following in vitro confirmation, we focused on 5-azacytidine, a DNMT1 (DNA methyltransferase-1) inhibitor, for further analysis. Azacitidine 47-60 DNA methyltransferase (cytosine-5) 1 Mus musculus 71-94 31802101-8 2020 Low doses of DNMT inhibitors (decitabine (DAC) and azacitidine (AZA)) exerted efficient anti-tumor effects in CAC, accompanied with upregulation of BAD and INPPL1 expression, and apoptosis induction. Azacitidine 51-62 DNA methyltransferase (cytosine-5) 1 Mus musculus 13-17 31802101-8 2020 Low doses of DNMT inhibitors (decitabine (DAC) and azacitidine (AZA)) exerted efficient anti-tumor effects in CAC, accompanied with upregulation of BAD and INPPL1 expression, and apoptosis induction. Azacitidine 64-67 DNA methyltransferase (cytosine-5) 1 Mus musculus 13-17